Evidence map›Paper›PMID 41113819›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2025

Enhanced Donor Lung Viability During Prolonged

Linar Faizov, Yerik Zuparov, Aiym Turarova, Zhuldyz Nurmykhametova, Aidyn Kuanyshbek, Rymbay Kaliyev, Anatoly Sergienko, Timur Lesbekov, Yuriy Pya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Time as a Therapeutic Ally: The Promise of Long-Term Solid Organ and Tissue Perfusion.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linar FaizovDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Yerik ZuparovDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Aiym TurarovaDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Zhuldyz NurmykhametovaDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Aidyn KuanyshbekDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Rymbay KaliyevDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Anatoly SergienkoDepartment of Bioengineering, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Timur LesbekovDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Yuriy PyaDepartment of OR with Mechanical Circulatory Support, National Research Cardiac Surgery Center, Astana, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The shortage of donor organs remains a significant obstacle to addressing the growing demand for lung transplantation. We have developed a mobile EVLP circuit utilizing extracorporeal membrane oxygenation (ECMO) technology. The goals of our study was to evaluate the safety of a cellular-based EVLP system and to assess the efficacy of continuous cytokine removal and the application of bronchodilators during prolonged EVLP. A total of 29 pigs, aged 6-18 months and weighing 93 ± 13.1 kg (mean ± SD), were used in the study. The lungs were randomly allocated into the following groups: Cytosorb group (n = 12), were perfused with an EVLP circuit containing a Cytosorb cartridge, and Control group (n = 12), where lungs were perfused with an EVLP circuit without a Cytosorb cartridge, Bronchodilator group (n = 5) consisted of lungs that were nebulized with a combined bronchodilator every 4 h after the initiation of ventilation and Control group (n = 5) inhaled the control solvent under the same settings. Our study demonstrates that whole blood based perfusate with continuous ultrafiltration for functioning lung in machine perfusion can be straightforward and efficient for at least 24 h. Additional cytokine removal had led to significant improvement of organ quality over 24 h of EVLP.

Indexed as

Extracorporeal Membrane OxygenationLungLung TransplantationOrgan PreservationPerfusionAnimalsBronchodilator AgentsCytokinesSwineTissue DonorsBronchodilator AgentsCytokinesbronchodilationCytosorbECMO technologyex vivo lung perfusionnormothermic machine perfusion

Identifiers

PMID41113819
PMCPMC12527967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.